Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab

BACKGROUND: Low‐density lipoprotein cholesterol (LDL‐C) is a risk factor for atherosclerotic cardiovascular disease (ASCVD). There are limited real‐world data on LDL‐C lowering with evolocumab in United States clinical practice. HYPOTHESIS: We assessed LDL‐C lowering during 1 year of evolocumab ther...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cardiol
Hlavní autoři: Desai, Nihar R., Wade, Rolin L., Xiang, Pin, Pinto, Lionel, Nunna, Sasikiran, Wang, Xin, Exter, Jason, Mues, Katherine E., Habib, Mohdhar, Chen, Chi‐Chang
Médium: Artigo
Jazyk:Inglês
Vydáno: Wiley Periodicals, Inc. 2021
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8119857/
https://ncbi.nlm.nih.gov/pubmed/33760276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.23600
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky